ReviewFrontiers in pharmacology2025
Bibliometric analysis of research trends on the combination of radiotherapy and PARP inhibitors in solid tumors.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Radiotherapy has served as a cornerstone in cancer treatment for over a century. However, the efficacy of radiotherapy is often compromised by the intrinsic and acquired radioresistance of tumors, which can lead to treatment failure and disease recurrence. Recent advancements in preclinical and clinical research have highlighted the potential synergistic efficacy of combining radiotherapy with poly-ADP-ribose polymerase inhibitors (PARPi), offering promising therapeutic avenues for solid tumors. This study employs bibliometric analysis to systematically evaluate the evolution, trends, and intellectual landscape of research on the combination of radiotherapy and PARPi in solid tumors. Methods: Publications addressing the combination of radiotherapy and PARPi for solid tumors between 2005 and 2024 were retrieved from the Web of Science Core Collection (WOSCC) database. Bibliometric assessments were conducted using VOSviewer and CiteSpace to analyze publication trends, collaborative networks, and research foci. Results: A total of 901 articles were included. The United States dominated research output, with the University of Texas MD Anderson Cancer Center identified as the most productive institution. Hannah Farmer emerged as the most frequently cited author. Keywords co-occurrence analysis revealed a thematic shift from foundational studies on molecular mechanisms, such as DNA damage response and mechanism of action of PARPi, toward clinical investigations evaluating combination therapy efficacy and safety in trials. Conclusion: This bibliometric analysis underscores the rapid growth of research on radiotherapy and PARPi combination therapy, with the United States maintaining a leading role due to its extensive scientific infrastructure and collaborative networks. The field has transitioned from mechanistic explorations to translational and clinical applications, reflecting progress toward therapeutic optimization. These findings provide a comprehensive overview of the knowledge structure within this domain and serve as a strategic reference for guiding future research priorities and clinical implementations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.